Episode 223: Oncogenic Viruses

Rio Bravo qWeek19mMay 8, 2026

Get the full intelligence

Search transcripts, export clips, track mentions, and explore all topics from “Episode 223: Oncogenic Viruses” inside PodZeus.

AI-Generated Summary

In Episode 223 of Rio Bravo Q Week, medical students Meher Poporai and Jeremy Pan dive into the world of oncogenic viruses—viruses that can cause cancer. They begin with a framework explaining three main mechanisms: direct oncogenesis (disrupting tumor suppressors like p53 and RB), chronic inflammation leading to DNA damage, and immune evasion that impairs the body’s ability to detect abnormal cells. The episode then explores key oncogenic viruses, including HPV (linked to cervical, anal, and oropharyngeal cancers), EBV (associated with Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma), hepatitis B and C (major causes of hepatocellular carcinoma), HTLV-1 (causing adult T-cell leukemia/lymphoma), HHV-8 (responsible for Kaposi’s sarcoma in immunocompromised patients), Merkel cell polyomavirus (linked to aggressive skin cancer), and HIV (which indirectly increases cancer risk by weakening immune surveillance). The hosts emphasize the importance of prevention through vaccination (HPV, Hep B), early screening, and antiretroviral therapy, highlighting how public health interventions like the HPV vaccine have led to near-zero infection rates in vaccinated populations. They conclude with actionable takeaways for clinical practice, including maintaining high suspicion for HPV-related cancers in young non-smokers and aggressive cancers in immunocompromised individuals. The episode underscores a powerful message: many cancers are preventable through vaccines and early detection. The hosts stress that oncogenic viruses represent a critical intersection of infectious disease and oncology, where prevention is not just possible but already transforming outcomes. They highlight the success of the HPV vaccine in Scotland, the curative potential of DAA therapy for Hep C, and the life-saving impact of ART in reducing HIV-associated cancers. The tone is optimistic and empowering, emphasizing that medicine has made remarkable strides in turning cancer prevention into a reality through targeted public health strategies.

Key Takeaways
1

HPV and Hep B vaccines are highly effective in preventing cancers; the HPV vaccine has led to zero cases in vaccinated populations in Scotland.

2

Persistent infection—not just exposure—is key to oncogenic virus-related cancer development.

3

Chronic inflammation from viruses like Hep C and EBV drives cancer through repeated DNA damage and mutation.

4

Immune suppression (e.g., from HIV) dramatically increases cancer risk by impairing tumor surveillance.

5

Early screening and treatment of underlying viral infections (e.g., Hep B/C, HIV) significantly reduce long-term cancer risk.

…and 3 more takeaways available in PodZeus

Chapters
0:00
3 min

Introduction and Framework for Oncogenic Viruses

If you told someone 50 years ago, we'd be vaccinating against cancer, they probably wouldn't have believed you, but it's amazing to see how far medicine has come.

Highlight
3:00
4 min

Human Papillomavirus (HPV) and Cancer Prevention

There were zero cases of HPV in adults who received the vaccine between 12 to 13 years of age. Zero is crazy.

Highlight
7:00
5 min

Epstein-Barr Virus (EBV) and Lymphomas

EBV’s role in B-cell immortalization and its association with Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma is explored. The hosts note its global cancer burden (240,000 cases/year) and the importance of clinical suspicion in diagnosis.

12:00
5 min

Hepatitis B and C: Liver Cancer Pathways

The ability to treat Hep C is just so beneficial to population health.

Highlight
17:00
5 min

Rare Oncogenic Viruses: HTLV-1, HHV-8, and Merkel Cell Polyomavirus

The episode covers HTLV-1 (adult T-cell leukemia), HHV-8 (Kaposi’s sarcoma), and Merkel cell polyomavirus (aggressive skin cancer). Emphasis is placed on clinical recognition, lack of routine screening, and the importance of biopsy and immunotherapy.

High-Impact Quotes
There were zero cases of HPV in adults who received the vaccine between 12 to 13 years of age. Zero is crazy.
Jeremy Pan5:37
Viral: 90.0
If you told someone 50 years ago, we'd be vaccinating against cancer, they probably wouldn't have believed you, but it's amazing to see how far medicine has come.
Meher Poporai1:37
Viral: 85.0
HIV isn't causing the mutations directly. It's mainly creating an environment where other viruses can drive cancer development more aggressively.
Jeremy Pan16:50
Viral: 80.0
Speakers

Hosts

Meher PoporaiJeremy Pan

Guest

Dr. Ariaza
Topics Discussed
oncogenic viruses95%cancer prevention90%vaccines and public health85%HPV and cervical cancer85%HIV and cancer risk80%immune surveillance80%hepatocellular carcinoma75%screening and early detection70%
People & Brands

Meher Poporai

person

15xPositive

Jeremy Pan

person

14xPositive

Human Papillomavirus

other

12xPositive

HIV

other

10xPositive

Epstein-Barr Virus

other

8xPositive

Hepatitis C

other

7xPositive

Hepatitis B

other

7xPositive

HPV vaccine

other

6xPositive

Antiretroviral therapy

product

6xPositive

HTLV-1

other

5xNeutral

Get the full intelligence

Search transcripts, export clips, track mentions, and explore all topics from “Episode 223: Oncogenic Viruses” inside PodZeus.

Start discovering podcast insights today

Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.

No credit card required • 7-day trial • Cancel anytime